Chiara Falcicchia
Michele Simonato
Gianluca Verlengia
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- 1Department of Medical Sciences, Section of Pharmacology, and Neuroscience Center, University of Ferrara and National Institute of Neuroscience, Ferrara, Italy
- 2School of Medicine, University Vita-Salute San Raffaele, Milan, Italy
A corrigendum on
New Tools for Epilepsy Therapy
by Falcicchia, C., Simonato, M., and Verlengia, G. (2018). Front. Cell. Neurosci. 12:147. doi: 10.3389/fncel.2018.00147
In the original article, we made the incorrect statement that non-viral vectors do not work in vivo, as below:
“Although the use of non-viral vectors could be attractive as they are generally safe, cheap and relative easy to produce, these approaches do not work in vivo”
This mistake was due to the fact that we meant to refer to epilepsy. Non-viral vectors have provided promising results for other applications, even if less for central nervous system disorders and in no case for epilepsy.
A correction has been made to section “Gene Therapy Approaches”, Paragraph 3:
In the past few years, the use of non-viral vectors has made a big step up for both in vitro and in vivo applications (Hardee et al., 2017). If compared to their viral counterpart, these tools are deemed to be generally safer, cheaper and relatively easier to produce. However, their employment for in vivo CNS targeting is still hindered by inadequate efficiency of transduction and transient expression of the transgene. At least so far, there is no evidence of efficacy for epilepsy treatment in preclinical or clinical studies by delivery of nucleic acids through non-viral systems.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
The original article has been updated.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Keywords: epilepsy, cell therapy, delivery devices, gene therapy, herpes-based vector
Citation: Falcicchia C, Simonato M and Verlengia G (2018) Corrigendum: New Tools for Epilepsy Therapy. Front. Cell. Neurosci. 12:212. doi: 10.3389/fncel.2018.00212
Received: 26 June 2018; Accepted: 27 June 2018;
Published: 11 July 2018.
Approved by:
Frontiers In Cellular Neuroscience Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2018 Falcicchia, Simonato and Verlengia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gianluca Verlengia, dmVybGVuZ2lhLmdpYW5sdWNhQGhzci5pdA==